Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Share-based Compensation (2016 - 2025)

Kiora Pharmaceuticals' Share-based Compensation history spans 11 years, with the latest figure at $234448.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 46.37% year-over-year to $234448.0; the TTM value through Dec 2025 reached $900236.0, up 37.11%, while the annual FY2025 figure was $900236.0, 37.11% up from the prior year.
  • Share-based Compensation reached $234448.0 in Q4 2025 per KPRX's latest filing, down from $254398.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $264864.0 in Q3 2023 to a low of $135941.0 in Q1 2023.
  • Average Share-based Compensation over 5 years is $198245.2, with a median of $182344.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: tumbled 37.04% in 2023, then soared 75.42% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $213169.0 in 2021, then rose by 1.29% to $215921.0 in 2022, then decreased by 15.55% to $182344.0 in 2023, then decreased by 12.16% to $160180.0 in 2024, then soared by 46.37% to $234448.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Share-based Compensation are $234448.0 (Q4 2025), $254398.0 (Q3 2025), and $262774.0 (Q2 2025).